Harmony Biosciences announced Q3 2026 net revenue of $269 million for WAKIX, driven by strong patient demand with 400 net patient additions, maintaining full-year guidance of $1.0 to $1.04 billion. The company reported favorable safety and tolerability data from a multiple-ascending dose study of BP-205, an investigational orexin-2 receptor agonist, with no serious adverse events. Phase 1b data for BP-205 is expected in Q1 2027, with Phase 2 studies planned for mid-2027. Additionally, a leadership transition will occur with Peter Anastasiou becoming CEO in January 2027. Harmony continues to advance its pipeline and protect its WAKIX franchise through ongoing legal actions and patent strategies.
Harmony Biosciences' Q3 financial results and clinical progress provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 18:41 WIB: out of 150 priced US health-sector stocks, 118 rose and 24 fell today. Notable movers include Centene Corp (CNC) at USD 70.40 with a 4.33% increase and a typical hold time of 43 days, Abeona Therapeutics Inc (ABEO) at USD 4.41 with a 3.76% rise and 100% buy order activity, and TransMedics Group Inc (TMDX) at USD 69.85 with a 3.73% gain and 100% buy order activity.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
